EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series

Mingfang Sun, Ling Wang, Xinghong Liu, Fei Xiao, Huanzi Dai

Clinical Kidney Journal · 01.08.2024 · 17 (8)

DOI: 10.1093/ckj/sfae178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 27.06.2024. Verfasst von Mingfang Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Army Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunoglobulin A nephropathy (IgAN) with podocytopathy is a rare pathological type of glomerular disease. The use of rituximab (RTX) in the treatment of glomerular diseases has increased in recent decades, but the efficacy of RTX in the treatment of patients with IgAN and podocytopathy has rarely been reported.

Methods

This was a single-centre retrospective study of IgAN patients with podocytopathy who were treated with RTX as second-line therapy was conducted at our centre from 2019 to 2022. The aim of this study was to investigate the efficacy and safety of RTX in IgAN patients with podocytopathy.

Results

Seven out of eight patients met the criteria for complete remission following RTX therapy. Only one patient experienced adverse events (infectious diarrhoea and pulmonary infection) and experienced relapse 6 months after RTX therapy. The maximum relapse-free time after RTX therapy was 20 months, while the maximum relapse-free time before RTX therapy was only 6 months. The number of relapses before RTX therapy (per year) was one to four; moreover, seven patients did not relapse and maintained remission at the last follow-up despite steroid withdrawal after RTX therapy.

Conclusion

Overall, RTX effectively reduced proteinuria, increased the maximum relapse-free time, reduced the number of relapses per year and helped patients stop steroid use as soon as possible. RTX also helped most patients achieve clinical remission. RTX appears to be an effective and safe alternative for treating IgAN patients with podocytopathy with steroid dependence or frequent relapse.

Schlagwörter

Stichwörter der Autor:innen

IgA nephropathypodocytopathyrituximab

Autor:innen und Institutionen

  • Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China.
  • Department of Nephrology, Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China.

Förderung

  • Army Medical University

Zitieren

APA

Sun, M., Wang, L., Liu, X., Xiao, F., & Dai, H. (2024). The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series. Clinical Kidney Journal, 17(8). https://doi.org/10.1093/ckj/sfae178

Vancouver

Sun M, Wang L, Liu X, Xiao F, Dai H. The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series. Clinical Kidney Journal. 2024;17(8). doi:10.1093/ckj/sfae178

BibTeX
@article{Sun2024,
  author = {Sun, Mingfang and Wang, Ling and Liu, Xinghong and Xiao, Fei and Dai, Huanzi},
  title = {The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series},
  journal = {Clinical Kidney Journal},
  year = {2024},
  volume = {17},
  number = {8},
  doi = {10.1093/ckj/sfae178}
}
Kostenlos starten →